Effectiveness of ustekinumab in patients with atopic dermatitis: analysis of real-world evidence

References

• Steinhoff M, Cevikbas F, Ikoma A, et al. Pruritus: management algorithms and experimental therapies. Semin Cutan Med Surg. 2011;30(2):127–137.
   PubMed Web of Science ®Google Scholar
• Bieber T. Atopic dermatitis. N Engl J Med. 2008;358:1483–1494.
   PubMed Web of Science ®Google Scholar
• Weidinger S, Beck LA, Bieber T, et al. Atopic dermatitis. Nat Rev Dis Primers. 2018;4(1):1.
   PubMed Web of Science ®Google Scholar
• Czarnowicki T, He H, Krueger JG, et al. Atopic dermatitis endotypes and implications for targeted therapeutics. J Allergy Clin Immunol. 2019;143(1):1–11.
   PubMed Web of Science ®Google Scholar
• Leung DY, Boguniewicz M, Howell MD, et al. New insights into atopic dermatitis. J Clin Invest. 2004;113:651–657.
   PubMed Web of Science ®Google Scholar
• Milner JD. IL-17 producing cells in host defense and atopy. Curr Opin Immunol. 2011;23:784–788.
   PubMed Web of Science ®Google Scholar
• Di Cesare A, Di MP, Nestle FO. A role for Th17 cells in the immunopathogenesis of atopic dermatitis? J Invest Dermatol. 2008;128:2569–2571.
   PubMedGoogle Scholar
• Kikly K, Liu L, Na S, et al. The IL-23/Th17 axis: therapeutic targets for autoimmune inflammation. Curr Opin Immunol. 2006;18:670–675.
   PubMed Web of Science ®Google Scholar
• Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1) [published correction appears in Lancet. 2008 May 31;371(9627):1838]. Lancet. 2008;371(9625):1665–1674.
   PubMedGoogle Scholar
• Agusti-Mejias A, Messeguer F, García R, et al. Severe refractory atopic dermatitis in an adolescent patient successfully treated with ustekinumab. Ann Dermatol. 2013;25(3):368–370.
   PubMed Web of Science ®Google Scholar
• Nic Dhonncha E, Clowry J, Dunphy M, et al. Treatment of severe atopic dermatitis with ustekinumab: a case series of 10 patients. Br J Dermatol. 2017;177(6):1752–1753.
   PubMed Web of Science ®Google Scholar
• Fernández-Antón Martínez MC, Alfageme RF, Ciudad BC, et al. Ustekinumab in the treatment of severe atopic dermatitis: a preliminary report of our experience with 4 patients. Actas Dermosifiliogr. 2014;105(3):312–313.
   PubMedGoogle Scholar
• Puya R, Alvarez-López M, Velez A, et al. Treatment of severe refractory adult atopic dermatitis with ustekinumab. Int J Dermatol. 2012;51(1):115–116.
   PubMed Web of Science ®Google Scholar
• Samorano LP, Hanifin JM, Simpson EL, et al. Inadequate response to ustekinumab in atopic dermatitis - a report of two patients. J Eur Acad Dermatol Venereol. 2016;30(3):522–523.
   PubMed Web of Science ®Google Scholar
• Wlodek C, Hewitt H, Kennedy CT. Use of ustekinumab for severe refractory atopic dermatitis in a young teenager. Clin Exp Dermatol. 2016;41(6):625–627.
   PubMed Web of Science ®Google Scholar
• Shroff A, Guttman-Yassky E. Successful use of ustekinumab therapy in refractory severe atopic dermatitis. JAAD Case Rep. 2014;1(1):25–26.
   PubMedGoogle Scholar
• Weiss D, Schaschinger M, Ristl R, et al. Ustekinumab treatment in severe atopic dermatitis: down-regulation of T-helper 2/22 expression. J Am Acad Dermatol. 2017;76(1):91–97.
   PubMed Web of Science ®Google Scholar
• Gittler JK, Shemer A, Suarez-Fariñas M, et al. Progressive activation of T(H)2/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. J Allergy Clin Immunol. 2012;130(6):1344–1354.
   PubMed Web of Science ®Google Scholar
• Koga C, Kabashima K, Shiraishi N, et al. Possible pathogenic role of Th17 cells for atopic dermatitis. J Invest Dermatol. 2008;128:2625–2630.
   PubMed Web of Science ®Google Scholar
• Brezinski EA, Armstrong AW. An evidence-based review of the mechanism of action, efficacy, and safety of biologic therapies in the treatment of psoriasis and psoriatic arthritis. Curr Med Chem. 2015;22:1930–1942.
   PubMed Web of Science ®Google Scholar
• Khattri S, Brunner PM, Garcet S, et al. Efficacy and safety of ustekinumab treatment in adults with moderate-to-severe atopic dermatitis. Exp Dermatol. 2017;26:28–35.
   PubMed Web of Science ®Google Scholar
• Saeki H, Kabashima K, Tokura Y, et al. Efficacy and safety of ustekinumab in Japanese patients with severe atopic dermatitis: a randomized, double-blind, placebo-controlled, phase II study. Br J Dermatol. 2017;177:419–427.
   PubMed Web of Science ®Google Scholar
• Noda S, Suarez-Fariñas M, Ungar B, et al. The Asian atopic dermatitis phenotype combines features of atopic dermatitis and psoriasis with increased Th17 polarization. J Allergy Clin Immunol. 2015;136:1254–1264.
   PubMed Web of Science ®Google Scholar
• Samuel RJ, Reynolds NJ. Ustekinumab for severe atopic dermatitis: an important negative study. Br J Dermatol. 2017;177(2):339–341.
   PubMed Web of Science ®Google Scholar
• Noda S, Krueger JG, Guttman-Yassky E. The translational revolution and use of biologics in patients with inflammatory skin diseases. J Allergy Clin Immunol. 2015;135(2):324–336.
   PubMed Web of Science ®Google Scholar
• Leung DY, Guttman-Yassky E. Deciphering the complexities of atopic dermatitis: shifting paradigms in treatment approaches. J Allergy Clin Immunol. 2014;134(4):769–779.
   PubMed Web of Science ®Google Scholar
• Czarnowicki T, Esaki H, Gonzalez J, et al. Early pediatric atopic dermatitis shows only a cutaneous lymphocyte antigen (CLA)(+) TH2/TH1 cell imbalance, whereas adults acquire CLA(+) TH22/TC22 cell subsets. J Allergy Clin Immunol. 2015;136(4):941–951.
   PubMed Web of Science ®Google Scholar
• Suarez-Fariñas M, Dhingra N, Gittler J, et al. Intrinsic atopic dermatitis shows similar TH2 and higher TH17 immune activation compared with extrinsic atopic dermatitis. J Allergy Clin Immunol. 2013;132:361–370.
   PubMed Web of Science ®Google Scholar
• Beck LA, Thaçi D, Hamilton JD, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med. 2014;371(2):130–139.
   PubMed Web of Science ®Google Scholar
• Ruzicka T, Hanifin JM, Furue M, et al. Anti-Interleukin-31 Receptor A Antibody for Atopic Dermatitis. N Engl J Med. 2017;376(9):826–835.
   PubMed Web of Science ®Google Scholar
• Simpson EL, Bieber T, Guttman-Yassky E, et al. Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. N Engl J Med. 2016;375(24):2335–2348.
   PubMed Web of Science ®Google Scholar
• Silverberg JI, Silverberg NB. Atopic Dermatitis: a heterogeneous disorder. Dermatol Clin. 2017;35(3):ix.
   PubMed Web of Science ®Google Scholar
• Holm JG, Thomsen SF. Omalizumab for atopic dermatitis: evidence for and against its use. G Ital Dermatol Venereol. 2019;154(4):480–487.
   PubMed Web of Science ®Google Scholar
• Snast I, Reiter O, Hodak E, et al. Are biologics efficacious in atopic dermatitis? A systematic review and meta-analysis. Am J Clin Dermatol. 2018;19(2):145–165.
   PubMed Web of Science ®Google Scholar
• McDonald BS, Jones J, Rustin M. Rituximab as a treatment for severe atopic eczema: failure to improve in three consecutive patients. Clin Exp Dermatol. 2016;41(1):45–47.
   PubMed Web of Science ®Google Scholar
• Puig L, Ruiz-Salas V. Long-term efficacy, safety and drug survival of ustekinumab in a Spanish cohort of patients with moderate to severe plaque psoriasis. Dermatology. 2015;230(1):46–54.
   PubMed Web of Science ®Google Scholar
• Heil PM, Maurer D, Klein B, et al. Omalizumab therapy in atopic dermatitis: depletion of IgE does not improve the clinical course – a randomized, placebo-controlled and double blind pilot study. J Dtsch Dermatol Ges. 2010;8(12):990–998.
   PubMed Web of Science ®Google Scholar
• Czarnowicki T, Malajian D, Shemer A, et al. Skin-homing and systemic T-cell subsets show higher activation in atopic dermatitis versus psoriasis. J Allergy Clin Immunol. 2015;136(1):208–211.
   PubMed Web of Science ®Google Scholar
• Czarnowicki T, Gonzalez J, Shemer A, et al. Severe atopic dermatitis is characterized by selective expansion of circulating TH2/TC2 and TH22/TC22, but not TH17/TC17, cells within the skin-homing T-cell population. J Allergy Clin Immunol. 2015;136(1):104–115.
   PubMed Web of Science ®Google Scholar
• Bieber T. Interleukin-13: targeting an underestimated cytokine in atopic dermatitis. Allergy. 2020;75(1):54–62.
   PubMed Web of Science ®Google Scholar
• Ishiuji Y, Umezawa Y, Asahina A, et al. Exacerbation of atopic dermatitis symptoms by ustekinumab in psoriatic patients with elevated serum immunoglobulin E levels: report of two cases. J Dermatol. 2018;45(6):732–734.
   PubMed Web of Science ®Google Scholar
• Lis-Święty A, Skrzypek-Salamon A, Arasiewicz H, et al. Atopic dermatitis exacerbated with ustekinumab in a psoriatic patient with childhood history of atopy. Allergol Int. 2015;64(4):382–383.
   PubMed Web of Science ®Google Scholar
• Kroll K, Spornraft-Ragaller P, Schild M, et al. Induction of atopic dermatitis under ustekinumab-therapy in psoriasis vulgaris. Aktuelle Dermatologie. 2014;40(83):3–81.
   Google Scholar
• Ishigame H, Kakuta S, Nagai T, et al. Differential roles of interleukin-17A and -17F in host defense against mucoepithelial bacterial infection and allergic responses. Immunity. 2009;30:108–119.
   PubMed Web of Science ®Google Scholar
• Chan JL, Davis-Reed L, Kimball AB. Counter-regulatory balance: atopic dermatitis in patients undergoing infliximab infusion therapy. J Drugs Dermatol. 2004;3:315–318.
   PubMedGoogle Scholar
• van Laarhoven AIM, van der Sman-Mauriks IM, Donders ART, et al. Placebo effects on itch: a meta-analysis of clinical trials of patients with dermatological conditions. J Invest Dermatol. 2015;135(5):1234–1243.
   PubMed Web of Science ®Google Scholar